{"url_path":"/sec/tvrd/8-k/2026-07-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-17","source_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-084627-index.html","accession_number":"0001104659-26-084627","cik":"0001346830","ticker":"TVRD","issuer_name":"Tvardi Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-084627-index.html","primary_entity_key":"0001346830","primary_entity_name":"Tvardi Therapeutics, Inc."},"word_count":88,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n** **\n\n**(d) Exhibits**\n\n** **\n\n**Exhibit No.**\n \n**Description**\n\n[5.1](tm2620743d1_ex5-1.htm)\n \n[Opinion of Cooley LLP.](tm2620743d1_ex5-1.htm)\n\n[23.1](tm2620743d1_ex5-1.htm)\n \n[Consent of Cooley LLP (contained in Exhibit 5.1).](tm2620743d1_ex5-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly\nauthorized.\n\n \n\n \nTVARDI THERAPEUTICS, INC.\n\n \n \n\nDate: July 17, 2026\nBy:\n/s/ Imran Alibhai\n\n \nName:\nImran Alibhai\n\n \nTitle:\nChief Executive Officer"}